SCM
ENGN icon

Silverarc Capital Management’s enGene Therapeutics ENGN Stock Holding History

Silverarc Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-263,841
Closed -$2.49M – 74
2024
Q2 		$2.49M Buy
+263,841
New +$3.38M 0.59% 48

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Silverarc Capital Management's ENGN Position: Q3 2024 in Review

Silverarc Capital Management sold out of enGene Therapeutics (ENGN) in Q3 2024, closing a stake of 263,841 shares — an estimated $2.49M sold.

Silverarc Capital Management first reported a position in ENGN in Q2 2024 and held it in 1 quarter. The position peaked at $2.49M in Q2 2024. 30 funds tracked by Wall St. Rank hold ENGN as of Q3 2024.

  • Silverarc Capital Management reported no remaining enGene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 263,841 enGene Therapeutics shares in Q3 2024, an estimated $2.49M.
  • Silverarc Capital Management first reported a position in enGene Therapeutics in Q2 2024 and held it in 1 quarter.
  • Silverarc Capital Management's enGene Therapeutics position peaked at $2.49M in Q2 2024.
  • 30 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2024.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.